Literature DB >> 10989264

Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions.

Y Noda1, H Kamei, T Mamiya, H Furukawa, T Nabeshima.   

Abstract

Repeated treatment with phencyclidine (PCP) prolonged the immobility time in a forced swimming test, compared with saline treatment, this behavioral change being regarded as avolition which is one of the negative symptoms of schizophrenia. In the present study, we investigated an involvement of serotonergic (5-HTergic) and dopaminergic systems in PCP-induced enhancement of immobility in mice, since an alteration in 5-HTergic and dopaminergic systems has been hypothesized in schizophrenia. The enhancing effect of PCP on the immobility in a forced swimming test was attenuated by clozapine, risperidone and olanzapine, which have serotonin (5-HT) and dopamine receptor antagonistic properties. These attenuating effects were significantly antagonized by a 5-HT(2) receptor agonist, (+/-)-2,5-dimethoxy-4-iodamphetamine (DOI) without affecting the immobility itself. (-)Sulpiride at a low dose and methylphenidate reversed the PCP-induced enhancement of immobility whereas pimozide, chlorpromazine and levomepromazine had no effect. There was no difference in the frequency of DOI-induced head twitches, which are mediated via 5-HT(2) receptors, between PCP- and saline-treated mice following the forced swimming test, indicating no functional changes in post-synaptic 5-HT(2) receptors. 5-HT utilization in the prefrontal cortex was increased, but dopamine utilization was decreased in mice showing PCP-induced enhancement of immobility. These results suggest that the enhanced effect of PCP on the immobility is mediated by imbalance of 5-HTergic and dopaminergic systems in the prefrontal cortex and could be used as a model of the negative symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989264     DOI: 10.1016/S0893-133X(00)00138-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  16 in total

1.  Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test.

Authors:  Barbara Langen; Rita Dost; Ute Egerland; Hans Stange; Norbert Hoefgen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-16       Impact factor: 4.530

2.  Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia.

Authors:  Elena A Spieker; Robert S Astur; Jeffrey T West; Jacqueline A Griego; Laura M Rowland
Journal:  Schizophr Res       Date:  2011-12-09       Impact factor: 4.939

Review 3.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 4.  Management of negative symptoms of schizophrenia.

Authors:  D C Javitt
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

5.  Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment.

Authors:  K A Newell; K Zavitsanou; X-F Huang
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

6.  Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Andres Gordillo; Shuhua Li; Elliott Richelson
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

7.  Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.

Authors:  John D Elsworth; Stephanie M Groman; J David Jentsch; Rodrigo Valles; Mohammed Shahid; Erik Wong; Hugh Marston; Robert H Roth
Journal:  Neuropharmacology       Date:  2011-08-23       Impact factor: 5.250

8.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.

Authors:  Taku Nagai; Rina Murai; Kanae Matsui; Hiroyuki Kamei; Yukihiro Noda; Hiroshi Furukawa; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2008-08-06       Impact factor: 4.530

9.  The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.

Authors:  Chris Rundfeldt; Katarzyna Socała; Piotr Wlaź
Journal:  J Neural Transm (Vienna)       Date:  2010-10-22       Impact factor: 3.575

10.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.